Search

Your search keyword '"B. Schwefel"' showing total 23 results

Search Constraints

Start Over You searched for: Author "B. Schwefel" Remove constraint Author: "B. Schwefel"
23 results on '"B. Schwefel"'

Search Results

1. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids

2. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

3. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies

4. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials

5. Elagolix Reduced Dyspareunia and Improved Health-Related Quality of Life in Premenopausal Women with Endometriosis-Associated Pain

6. Impact of Elagolix on Health-Related Quality of Life Among Patients with Moderate to Severe Endometriosis-Associated Pain: Analysis of EQ-5D-5L Data from a Phase III Randomized Controlled Trial

8. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

9. Long-Term Safety and Efficacy of Elagolix Treatment in Women with Endometriosis-Associated Pain: Primary Results From Two Phase 3 Extension Studies

10. Maintenance of endometriosis-associated pain reduction and quality of life improvement in phase 3 extension studies with elagolix

11. Reductions in endometriosis-associated pain among elagolix-treated women are consistent across a range of baseline characteristics

12. Long-Term Safety and Efficacy of Elagolix Treatment in Women With Endometriosis-Associated Pain [11OP]

14. The effect of elagolix on the endometrium: safety results from two randomized, placebo-controlled studies in women with endometriosis-associated pain

15. Use of elagolix for the management of endometriosis-associated pain: secondary efficacy results from two randomized, placebo-controlled studies

16. Long-term effect of elagolix on bone mineral density: results from two phase 3 extension studies in women with endometriosis-associated pain

17. O-GYN-MD-126 Primary Efficacy and Safety Results from Two Double-Blind, Randomized, Placebo-Controlled Studies Of Elagolix, an Oral Gonadotropin-Releasing Hormone Antagonist, in Women With Endometriosis-Associated Pain

18. The impact of elagolix on quality of life in women with endometriosis-associated pain: results from two randomized, placebo-controlled studies using the endometriosis health profile questionnaire

19. Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies

20. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.

21. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.

22. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.

23. Transformation of epithelial cells through recruitment leads to polyclonal intestinal tumors.

Catalog

Books, media, physical & digital resources